Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [404]

Managing strategies for lung, head and neck cancer

Dr William Nassib William Junior – MD Anderson, Houston, TX, USA

Managing strategies for lung, head and neck cancer ( Dr William Nassib William Junior – MD Anderson, Houston, TX, USA )

vandetanib improves PFS in thyroid cancer

Dr Enrique Grande - Hospital Universitario Ramón y Cajal, Madrid, Spain

vandetanib improves PFS in thyroid cancer ( Dr Enrique Grande - Hospital Universitario Ramón y Cajal, Madrid, Spain )

Raising awareness about head and neck cancer through the Make Sense campaign

Prof Jean-Louis Lefebvre, Northern France Comprehensive Cancer Centre, Lille...

Raising awareness about head and neck cancer through the Make Sense campaign ( Prof Jean-Louis Lefebvre, Northern France Comprehensive Cancer Centre, Lille, France )

Targeted therapy for iodine-refractory thyroid cancer

Dr Makoto Tahara - National Cancer Center Hospital East, Kashiwa, Japan

$Targeted therapy for iodine-refractory thyroid cancer ( Dr Makoto Tahara - National Cancer Center Hospital East, Kashiwa, Japan )$

Improvements in progression free survival for patients with metastatic head and...

Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium

Improvements in progression free survival for patients with metastatic head and neck cancer using second-line afatanib ( Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium )

Second-line afatinib significantly improves PFS in metastatic head and neck...

Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium

Second-line afatinib significantly improves PFS in metastatic head and neck cancer ( Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium )

Networking and collaborating across borders in sub-Saharan Africa

Dr Shubhra Ghosh - Project Director of Global Programs, MD Anderson Cancer...

Networking and collaborating across borders in sub-Saharan Africa ( Dr Shubhra Ghosh - Project Director of Global Programs, MD Anderson Cancer Centre, Houston, USA )

Phase III SELECT trial shows lenvatinib to be effective in resistant thyroid...

Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France

Phase III SELECT trial shows lenvatinib to be effective in resistant thyroid cancer ( Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France )

ASCO 2014 roundup

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

ASCO 2014 roundup ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

Lapatinib not found to be beneficial in head and neck cancer with high risk of...

Prof Kevin Harrington - Institute of Cancer Research, London, UK

Lapatinib not found to be beneficial in head and neck cancer with high risk of recurrence ( Prof Kevin Harrington - Institute of Cancer Research, London, UK )

Lenvatinib yields high response rates and delays progression in radioiodine...

Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France

Lenvatinib yields high response rates and delays progression in radioiodine-resistant, advanced differentiated thyroid cancer ( Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France )

Phase II trial shows dacomitinib benefits a subgroup of patients with head and...

Dr Byoung Chul Cho - Yonsei University College of Medicine, Seoul, Republic of...

Phase II trial shows dacomitinib benefits a subgroup of patients with head and neck cancer ( Dr Byoung Chul Cho - Yonsei University College of Medicine, Seoul, Republic of Korea )

More from ecancer